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ABSTRACT
Background COVID-19 mitigation strategies have been 
challenging to implement in resource- limited settings due 
to the potential for widespread disruption to social and 
economic well- being. Here we predict the clinical severity 
of COVID-19 in Malawi, quantifying the potential impact 
of intervention strategies and increases in health system 
capacity.
Methods The infection fatality ratios (IFR) were predicted 
by adjusting reported IFR for China, accounting for 
demography, the current prevalence of comorbidities and 
health system capacity. These estimates were input into an 
age- structured deterministic model, which simulated the 
epidemic trajectory with non- pharmaceutical interventions 
and increases in health system capacity.
Findings The predicted population- level IFR in Malawi, 
adjusted for age and comorbidity prevalence, is lower than 
that estimated for China (0.26%, 95% uncertainty interval 
(UI) 0.12%–0.69%, compared with 0.60%, 95% CI 0.4% 
to 1.3% in China); however, the health system constraints 
increase the predicted IFR to 0.83%, 95% UI 0.49%–
1.39%. The interventions implemented in January 2021 
could potentially avert 54 400 deaths (95% UI 26 900–97 
300) over the course of the epidemic compared with an 
unmitigated outbreak. Enhanced shielding of people aged 
≥60 years could avert 40 200 further deaths (95% UI 
25 300–69 700) and halve intensive care unit admissions 
at the peak of the outbreak. A novel therapeutic agent 
which reduces mortality by 0.65 and 0.8 for severe and 
critical cases, respectively, in combination with increasing 
hospital capacity, could reduce projected mortality to 2.5 
deaths per 1000 population (95% UI 1.9–3.6).
Conclusion We find the interventions currently used in 
Malawi are unlikely to effectively prevent SARS- CoV-2 
transmission but will have a significant impact on 
mortality. Increases in health system capacity and the 
introduction of novel therapeutics are likely to further 
reduce the projected numbers of deaths.
INTRODUCTION
As of 15 March 2021, the novel coronavirus 
SARS- CoV-2 had spread throughout every 
continent, with over 100 million cases and 
2.5 million deaths reported worldwide.1 Case 
numbers in the African continent continue 
to rise, and until widespread deployment of 
an effective vaccine, there is a critical reliance 
on non- pharmaceutical interventions (NPI) 
to reduce transmission. These measures 
include isolation of suspected/confirmed 
cases, contact tracing, social distancing, travel 
restrictions, face covering, school and work-
place closures, and shielding of the most 
vulnerable.2–5
By 1 January 2021, Malawi was experiencing 
a second wave of infections, and additional 
restrictions were placed on the population. 
Schools and workplaces were closed in many 
districts; large gatherings and public events 
were banned; but a full lockdown has been 
prohibited due to concerns around the 
implications on vulnerable populations.6 
The impact of NPI on SARS- CoV-2 trans-
mission in Malawi depends critically on the 
local context such as population behaviour 
(including uptake of and compliance with 
such measures), population movement and 
contact patterns (Malawi is over 80% rural 
Strengths and limitations of this study
 ► This is the first study to date which combines 
country- specific infection fatality ratios (IFRs) of 
COVID-19 for Malawi adjusted for comorbidity 
prevalence and with consideration of the prevailing 
health system constraints and the impact of these 
constraints on mortality rates.
 ► An age- structured deterministic model was used to 
characterise the spread of SARS- CoV-2 throughout 
Malawi using the Malawi- specific adjusted IFR.
 ► The impacts of non- pharmaceutical interventions, 
novel therapeutics and hospital capacity were an-
alysed, and the effects on incidence, mortality and 
hospital demand are presented.
 ► The IFR used as the baseline, from which we in-
ferred the adjusted IFR for Malawi, and some key 
parameters used in the simulation modelling relied 
on data from outside sub- Saharan Africa due to the 
limited numbers of cases there and might therefore 
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and many rely on subsistence farming) and health system 
capacity.7
The impact of NPI can be summarised as a change in 
the effective reproduction number R
t
, which represents 
the average number of secondary infections resulting 
from one infected case. Studies based on high- income 
countries have shown that strict interventions such as 
lockdown, where population movement is limited to 
essential travel and most public facilities and trans-
port links are closed, have shown the most success in 
reducing transmission.3 4 8–10 However, major restrictions 
to working practices or public transport may have cata-
strophic implications in sub- Saharan Africa, where many 
have limited financial capacity to withstand income 
shocks and no access to social protection programmes.11 
Face coverings have been recommended by WHO as one 
possible intervention which could reduce transmission 
of SARS- CoV-2 with minimal socioeconomic implications 
despite a lack of high- quality evidence.12 13 Nevertheless, 
many countries (including Canada, South Korea and 
the UK), have made face coverings mandatory in public 
spaces.
A key priority during this emerging pandemic is esti-
mating clinical severity and health system requirements. 
Current oxygen capacity in hospitals may not be suffi-
cient to give supportive care to large numbers of severe 
COVID-19 cases; 65% of 34 hospital wards in Malawian 
hospitals recently assessed had (what was considered 
pre- COVID-19) adequate access to oxygen and priority 
is now being given to scaling up access and supplies 
urgently.14 15 Early studies suggest oxygen supplementa-
tion could reduce the need for mechanical ventilation 
and lower the risk of death.16 Additionally, several ther-
apeutic agents, such as tocilizumab and dexamethasone, 
have been effective in improving patient outcomes, 
although none so far have been widely tested in sub- 
Saharan Africa.17 18
Infection fatality ratios (IFR), defined as the number 
of deaths divided by the number of infections, are 
challenging to estimate, particularly in an emerging 
outbreak, due to the difficulties in identifying the true 
number of infected people (both asymptomatic and 
symptomatic). IFR are strongly dependent on age, and 
the majority of deaths reported early in the epidemic 
were among those aged over 60 years.19–21 There is 
also a growing body of evidence on the elevated risk of 
mortality with certain underlying comorbidities, such as 
cardiovascular disease (CVD), diabetes, chronic obstruc-
tive pulmonary disease (COPD) and infectious diseases, 
for example, HIV, tuberculosis (TB) and malaria.22–25 
The majority of these data were reported from high- 
income settings, which have borne the highest burden 
of COVID-19 disease recorded so far. It is not yet clear 
how these risk factors will affect COVID-19 severity in 
countries like Malawi, which have a younger population 
overall, but a high prevalence of infectious diseases and 
untreated chronic conditions.
Objectives
Three objectives form the focus of this paper: (1) to 
predict disease severity caused by SARS- CoV-2 in the 
Malawian population, given its demographic structure, 
the prevalence of key comorbidities and health system 
capacity; (2) to examine the potential impact of a range 
of NPI that have been or could be used in Malawi; and on 
that basis, (3) to investigate the potential extent to which 
increasing health system capacity and/or providing ther-
apeutics could contribute to reducing deaths due to 
SARS- CoV-2 infection.
METHODS
We present the methods in three sections that relate to 
each of our aims.
Predictions of IFR in Malawi
Our approach uses data on age- specific IFR from China 
(one of the few studies which applies demography- 
adjusted underascertainment corrections) and then 
makes adjustments based on the demography and relative 
burdens of diseases relevant to COVID-19 risk between 
China and Malawi, making assumptions about the 
extent to which each disease affects IFR and the extent 
and impact of healthcare available.21 First, we predict 
IFR by age under the assumption of similar availability 
and impact of healthcare. We then use these predicted 
IFR and adjust for the potential impact of a constrained 
healthcare system in Malawi, making assumptions on the 
effect of treatment on mortality rates of severe and crit-
ical cases. The predicted IFR therefore represents pooled 
estimates of those receiving and not receiving care.
Predicted IFR with an unconstrained health system
The prevalence of HIV (virally suppressed and unsup-
pressed), active TB, clinical malaria, CVD, COPD, hyper-
tension, diabetes (types I and II), obesity (defined as Body 
Mass Index of ≥28 kg/m2 according to Chinese criteria 
and ≥30 kg/m2 using Malawian criteria) and malnutrition 
were extracted for Chinese and Malawian populations 
(see online supplemental figure 1 and online supple-
mental table 1 for data sources). We created a unified risk 
factor for ‘metabolic syndrome’, defined as the presence 
of at least one of the following conditions which tend 
to be clustered within individuals: CVD, hypertension, 
obesity and diabetes. The plausible range for the risks 
of mortality due to metabolic syndrome was taken as the 
outer bounds of the relative risks reported for each of the 
pooled conditions. Given the considerable uncertainty 
in these estimates along with likely differences across 
settings, we sample from a wide range of relative risk 
values for each comorbidity (online supplemental table 
2).
The baseline age- distributed IFR were derived from 
those published by Verity et al for cases reported in main-
land China, using linear interpolation on the log scale to 
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bands reported.21 Adjusted IFR by age for Malawi were 
computed as follows:
1. Lognormal distributions were derived for each of the 
age- distributed IFR from China such that the mean 
matched the mean IFR, and 95% of the probability 
mass fell inside the reported 95% bounds. Uniform 
distributions were defined for the relative risks of mor-
tality due to COVID-19 for each comorbidity covering 
the range described in online supplemental table 2.
2. Age- specific IFR and relative risks of mortality with co-
morbidities were sampled from the defined distribu-
tions.
3. Age- distributed IFR for a theoretical population with 
no comorbidities (IFR*
a
) were computed using the 













 was the sampled IFR in setting h 
(where h is China); i is the index for each comorbidity; 
r
i
 is the sampled relative risk of mortality for each con-
dition; and c
i,h,a
 is the prevalence of each comorbidity 
in setting h. All terms except relative risk values were 
indexed by age group a, assuming that there are no 
interactions between age and relative risk of death due 
to comorbidity.











5. Steps 2–4 were repeated 1000 times and the median 
adjusted IFR and uncertainty intervals (UIs) were cal-
culated as the 50th, 2.5th and 97.5th quantiles from 
the sampled estimates.
A summary for the average IFR for Malawi was obtained 
by weighting the age- specific IFR by the proportion of the 















 is the number of persons in that age group. 
The analysis was repeated using data on IFR from Brazil 
to determine whether the choice of primary data would 
affect the predicted IFR in Malawi.
This method assumed that the differences in IFR 
between settings are driven by the presence of comorbidi-
ties and differences in the age structure of the population.
Predicted IFR adjusting for health system constraints
The effect of access to and quality of healthcare was 
accounted for through the following additional steps:
1. Parameter sets defining the proportion of COVID-19 
cases requiring different levels of hospital care (severe 
or critical) were generated using rejection sampling on 
the basis of (1) prior information from high- income 
settings and (2) assumptions for mortality according to 
disease severity with treatment (online supplemental 
table 3).
2. These estimates of disease severity were used in the 
simulation model (detailed in the following section) 
to simulate epidemic trajectories over 365 days without 
NPI, where the availability of hospital care was limited 
to the level currently prevailing in Malawi.
3. The induced overall IFR in Malawi, given the current 
healthcare system constraints at the end of the epidem-
ic, was ‘number who died of COVID-19/number ever 
infected with SARS- CoV-2’.
Further details are provided in the Supplementary 
Information.
The resulting population- level IFR predictions for 
Malawi were compared with China using Monte Carlo 
simulation. IFR values for China were sampled 1000 times 
from the lognormal distributions for comparison and the 
Kolmogorov- Smirnov (KS) test statistic was computed, 
producing a KS test statistic distribution.
Estimates of the potential impact of NPI on transmission of 
SARS-CoV-2
The COVID-19 model of Walker et al was used to make 
projections of the spread of SARS- CoV-2 in Malawi under 
a number of NPI scenarios.26 Briefly, the deterministic 
model comprises an age- structured Susceptible- Exposed- 
Infected- Recovered (SEIR) compartmental framework 
which describes the transmission of SARS- CoV-2 through 
an otherwise homogenous population. The contact rates 
between age groups were derived from the Manicaland 
study in Zimbabwe (online supplemental table 4).27 
Infected (and infectious) cases were classified as mild 
(not requiring care), severe (requiring hospitalisation/
oxygen) and critical (requiring intensive care unit (ICU)/
mechanical ventilation) with the likelihood of receiving 
care constrained by the prevailing health system capacity. 
We assumed that not all critical cases required mechan-
ical ventilation, but for those that do, access to an ICU 
bed also indicates availability of mechanical ventilation. 
In each infected stage, there was a probability of death, 
derived from multinational analyses from data in China, 
the UK and the USA. It was assumed that hospitalised 
cases would not contribute to transmission. In the case 
of a person needing care but the health system capacity 
being exhausted, the person was exposed to a risk of 





=2, which was a central value for the esti-
mates of R
t
 in Malawi immediately prior to the second 
wave and varied this between 1.5 and 2.5 to reflect the 
uncertainty in this assumption.28 At the start of the 
simulation, 20 cases were seeded in age groups 35–54, 
reflecting the ages of those who were most likely to be 
working or travelling and acquired infection. The popu-
lation was considered to be fully susceptible during this 
simulated second wave due to waning immunity following 
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newer strains capable of evading pre- existing immune 
responses.29
NPI strategies
The NPIs that were in place at the start of the second wave 
are summarised in table 1. We additionally considered 
the potential impact of shielding those aged ≥60 years 
and lockdown. The duration of lockdown varied between 
6 and 24 weeks, whereupon the previously implemented 
intervention strategies were resumed. The trigger day for 
the implementation of NPI was when the rate of deaths 
exceeded 1.0 death per 100 000 population per week.
Face coverings were analysed as an incremental inter-
vention on top of the existing measures, and we explored 
a full range of values for efficacy and proper usage, 
assuming that the current measures in place remained 
for the duration of the simulation. We did not distinguish 
between household and non- household transmission and 
assumed adherence and efficacy jointly reduced the risk 
of transmission to the whole population.
The low numbers of deaths reported to date in Malawi 
coupled with the high potential for under- reporting make 
formal calibration to surveillance data problematic. We 
opted, therefore, to present a hypothetical scenario using 
plausible estimates for transmission rates in this setting 
and incorporating uncertainty around key assumptions.
We ran each simulation 1000 times over 365 modelled 
days using the sampled parameter sets for disease severity 
(see previous discussion). The outcomes of each inter-
vention on the daily number infected, health system 
requirements (broken down by severity) and deaths are 
presented.
Estimates of the impact of increasing health system capacity
The projected impact of increasing the number of non- 
intensive care hospital beds plus availability of oxygen 
and the introduction of a novel therapeutic agent were 
examined, assuming that the current intervention strate-
gies would remain in place indefinitely. We simulated an 
increase in hospital bed capacity (plus access to oxygen) 
by up to 100% from the trigger day of when the rate of 
deaths exceeded 1.0 deaths per 100 000 population per 
week, presenting the resulting impact on the cumulative 
number of deaths projected to occur over the epidemic. 
Additionally, the impact of a novel therapeutic agent was 
analysed, assuming a proportional reduction in mortality 
for severe and critical cases (0.65 and 0.8, respectively, 
which is of the same order of magnitude as indicated 
in the Randomised Evaluation of COVID-19 Therapy 
(RECOVERY) trial on dexamethasone, but the modelled 
agent is hypothetical) applicable to all age groups.17 We 
assumed that the therapeutic agent could be adminis-
tered to those in need even if hospital beds or ICU beds 
were not available.
All analyses were conducted in R statistical software 
V.3.6.3 (https://www. r- project. org/).
Data sharing agreement
Source code and supporting documentation for the SEIR 
model are available online (https://githubcom/mrc-ide/
squire). All data used in the analyses are publicly available 
and sources have been listed for each.
Patient and public involvement
Patients and/or the public were not involved in the 
design, conduct, reporting or dissemination plans of this 
research.
Role of the funding source
The funders of this study had no role in study design, data 
analysis, data interpretation or writing of the report. All 
Table 1 List of the interventions under consideration along with their implementation in the model
Strategy Implementation
Current situation Assumed to be in place at the start of the outbreak
Workplaces are closed; public events are banned; restrictions on 
gatherings are in place; public transport is reduced.




Dates and details of individual non- pharmaceutical interventions 
are reported by OxCGRT.6
Enhanced shielding:
Current situation, plus
shielding of those aged ≥60 years
Reduce contact rates by 60% for populations aged ≥60 years in 
addition to the reduction in R
t
 mentioned previously.
It is implemented after a trigger is reached.*
Lockdown:
Current situation plus:
Stay- at- home requirements
School closures
Enforcement of social distancing in excepted businesses
Prohibition of public transportation
Prohibition of all gatherings outside household




It is implemented after a trigger is reached.*
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authors had access to all data in the study and accept final 
responsibility for the decision to submit for publication.
RESULTS
Predictions of infection fatality ratios in Malawi
Under the assumption of similar healthcare availability, 
the predicted age- specific IFR for Malawi are higher for 
every age group than those reported in China. However, 
the predicted population- weighted IFR is lower (IFR 
0.26%, 95% UI 0.12%–0.69%, compared with 0.6%, 
95% CI 0.40% to 1.30% in China) due to the younger 
average age of the population (figure 1). Incorporating 
health system constraints through the simulation model 
results in significantly higher age- specific IFR for Malawi 
(p<0.05, KS test for all age groups), although the 
population- weighted estimate is not significantly different 
from that reported for China (overall IFR 0.83%, 95% UI 
0.49%–1.39%). When using the Brazil data, the adjusted 
population- weighted IFR for Malawi assuming no health 
system constraints is 0.48% (95% UI 0.33%–0.64%), 
compared with 0.26% (95% UI 0.12%–0.69%) when 
using the Chinese data (online supplemental figure 2).
Estimates of the potential impact of NPI on transmission of 
SARS-CoV-2
The projected unmitigated scenario is presented as 
counterfactual, showing what could occur had no inter-
ventions been introduced (figure 2). With the current 
interventions in place and assumed to be in place indef-
initely, we estimate approximately 54 400 deaths (95% 
UI 26 900–97 300) could be averted over the course of 
the epidemic compared with an unmitigated scenario 
in which 134 300 deaths (95% UI 82 100–222 500) are 
projected to occur (table 2). Enhanced shielding of 
people aged ≥60 years could avert a further 40 200 deaths 
(95% UI 25 300–69 700) and halve ICU admissions at the 
peak of the outbreak. These measures would also delay 
the spread of infection, shifting the peak in infections by 
approximately 66 days.
Figure 1 Predicted infection fatality ratios for the Malawian 
population with unconstrained and constrained healthcare 
(according to current health system capacity) compared with 
estimates reported from China.
Figure 2 Impact of NPI compared with a baseline (unmitigated) scenario on the daily incidence per 1000 population (A), the 
cumulative deaths per 1000 population (B), the percentage of hospital beds that are required (C) and the number of ICU beds 
that are required (D). The unmitigated scenario represents the counterfactual situation had no interventions been introduced. 
The current situation reflects the NPI adopted by Malawi at the start of the second wave. Enhanced shielding refers to reducing 
contact rates of people aged ≥60 years. Lockdown is the adoption of stringent social distancing policies. Further details are 
presented in table 1. The trigger date is shown with a vertical grey dashed line. The red horizontal dashed line shows the 
capacity of the health system for non- intensive care (C). ICU capacity comprises 25 ICU beds and 16 mechanical ventilators. 
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The predicted age distribution of infected people at 
the peak of the epidemic shows that the majority of infec-
tions occur in the younger ages (<20 years) which make 
up >50% of the population and have high contact rates 
(online supplemental figure 3), although only 1.3% of 
deaths occur in that group. There is, however, consider-
able uncertainty around the prevalence and impact of 
comorbidities such as HIV and malnutrition in these age 
groups. The majority of projected deaths occur in those 
aged over 70 years.
Of the mitigation strategies modelled, long- term lock-
down has the largest impact, bringing the infection rate 
down to 275 infections per 1000 population (95% UI 
224–327 per 1000 population) and the mortality rate 
to 1.8 deaths per 1000 population (95% UI 1.4–2.2 per 
1000 population, equivalent to 33 800 deaths, 95% UI 
26 600–41 900; table 1). Applying lockdown over 6, 12 
and 24 weeks delays the peak incidence, reducing the 
size of the outbreak and maintaining hospital require-
ments below capacity, which in turn reduces mortality 
rates (online supplemental figure 4). The impact of 
each intervention with R
t
=1.5 and 2.5 is shown in online 
supplemental table 6).
With current interventions in place, coverage of face 
coverings would need to exceed 60% (30% with shielding 
implemented simultaneously) with a minimum efficacy 
of 50% in order to reduce the projected R
t
 to below 1 
(figure 3).
Estimates of the impact of increasing health system capacity
Increasing capacity for non- intensive care (general 
hospital beds with oxygen availability) by 50% reduces the 
projected mortality rate to 3.7 deaths per 1000 population 
(95% UI 2.8–5.3) compared with 4.2 (95% UI 2.9–6.5) 
under the current scenario (online supplemental table 
7). Doubling hospital and oxygen capacity could margin-
ally reduce this further to 3.5 deaths per 1000 population 
(95% UI 2.8–4.7). Introducing a novel therapeutic agent 
that is capable of reducing mortality by 0.6 for severe cases 
and by 0.85 for critical cases, in combination with a 50% 
scale- up in hospital capacity, reduces projected deaths to 
2.5 deaths per 1000 population (95% UI 1.9–3.6, figure 4).
Table 2 Outputs from intervention strategies over 365 days
Unmitigated Current situation Enhanced shielding Lockdown


































All values are medians of 1000 simulations using the sampled parameter sets for disease severity. Numbers of hospital and ICU beds are 
rounded to the nearest 100.
Figure 3 Impact of face covering (A) and face covering plus enhanced shielding (B) on the total number of deaths per 1000 
population projected to occur over 365 days. The full range of values for % efficacy and % proper use (adherence) is presented. 
The current interventions are assumed to remain in place. The isoclines (green lines) represent the estimated R
t
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DISCUSSION
The results shown here give several important insights 
into the potential spread and severity of SARS- CoV-2 
infection in Malawi and what can be done to prepare for 
it.
First, under the assumption of similar access to health-
care, overall population- weighted IFR are lower than the 
reported values for China, consistent with findings from 
Brazeau et al (estimates for low- income countries 0.23, 
95% prediction interval 0.14–0.42) due to the younger 
average age of the population.21 30 As the availability of 
healthcare is much lower in Malawi, the overall expecta-
tion for IFR increases to 0.83%, 95% UI 0.49%–1.39%, 
within the range of estimates reported across the Amer-
icas, Asia and Europe (overall IFR 0.70, 95% CI 0.57 to 
0.82, range 0.28–0.89).31 Estimates of mortality in Uganda 
follow a similar trend, with a lower predicted disease 
burden than the comparator regions (Europe, America 
and China) and the majority of risk arising indirectly 
due to disruptions to the health service.32 Other studies 
have also reported a differential risk of severe disease in 
African settings compared with European countries due 
to underlying health conditions, although there is consid-
erable uncertainty in these analyses.33 34
Second, we find that the intervention strategies that have 
been implemented so far in Malawi would be unlikely to 
suppress or substantially mitigate the epidemic. Although 
lockdowns have been highly effective across a number of 
settings, they may be impractical in Malawi for a number 
of reasons.3 35 36 Approximately 50% of the Malawian 
population lives in poverty, meaning there is no finan-
cial buffer if people are unable to earn money.36 37 The 
disruptions to food production and delivery chains are 
likely to impact those who are most vulnerable, with food 
shortages likely to occur within days of lockdown being 
implemented.
We find that, similar to other studies, shielding of the 
older population (plus other vulnerable populations, 
such as people living with HIV or TB) would be effective 
in significantly reducing the death rate.8 38 The practical-
ities of moving elderly people into separate accommo-
dation in the African context are uncertain at best, but 
it is a potentially risky strategy as a single imported case 
could have devastating effects. In high- income countries, 
this strategy has proven difficult with outbreaks occurring 
in many nursing homes.39 Designating shielded house-
holds, or even single rooms within a household may be a 
viable strategy in Malawi, which has an extensive network 
of community health workers who could facilitate and 
support such measures.
Given the difficult choices facing decision- makers in 
Malawi and elsewhere, it is not surprising that signifi-
cant attention has turned to less disruptive strategies for 
restricting some population movement and advocating 
use of face coverings, a putatively low- cost and readily 
available means of reducing transmission risk.40 Delaying 
the epidemic by even a few months could allow time for 
new vaccines to be delivered and for further therapeutics 
to be tested and introduced.17 41 42 Additional interven-
tions, such as testing (test, trace and isolate) and local 
quarantining, could have a significant impact on the 
spread of infection and have been regularly used for case- 
finding and containment for HIV and TB in low- income 
and middle- income countries.43–46 However, they are 
extremely intensive and difficult to implement at a large 
scale and therefore may not be a feasible option for miti-
gating the outbreak in Malawi.
Third, we find that increases in certain types of capacity 
in the hospital may contribute to reducing deaths. The 
current priorities for COVID-19 response in Malawi are 
to distribute vaccines to health workers and significantly 
expand access to oxygen concentrators.15 47 There are 
likely to be improvements to long- term morbidity and 
lung health if severe cases receive oxygen when required, 
combined with reduced probability of requiring mechan-
ical ventilation, although we do not capture this here. 
There is an urgent need for further data to analyse the 
longer- term impacts of COVID-19 infection to inform 
this. Incorporating the predicted impact of a vaccine, 
prioritised for health workers, is not possible using this 
model as we do not capture occupation- based exposure 
risks. WHO strongly recommends systemic corticoste-
roid therapy (dexamethasone) for severe COVID-19 
infections, either alone or in combination with other 
drugs, which may reduce mortality and the need for 
mechanical ventilation.41 The impact of these therapies 
Figure 4 Projected total numbers of deaths per 1000 population over 365 days with increases in hospital capacity (and 
oxygen) and a novel therapeutic agent. The points show the median of 1000 simulations, with 2.5th and 97.5th uncertainty 
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in sub- Saharan Africa is not yet well documented and is 
likely to be affected by coinfections, particularly HIV and 
TB, coupled with late presentation to care.
The potential risk of nosocomial transmission is high, 
compounded by global shortages in personal protective 
equipment (PPE).48 In response, the Ministry of Health 
in Malawi developed COVID-19 treatment centres away 
from central hospitals and developed reusable PPE 
equipment to supplement those already acquired.49 We 
optimistically assume here that hospitalised cases are 
isolated and do not contribute to onwards transmission 
either in the community or to healthcare workers, which 
may bias our estimates of disease spread. Additionally, 
discounting this risk lowers the expected impact of NPI. 
Other modelling studies have shown variable risks in 
within- hospital transmission, with Evans et al suggesting 
up to 89% of infections in healthcare workers in England 
were acquired within the health system and Treibel et al 
finding the majority of these infections were acquired 
through community transmission.48 50
The unadjusted IFR that we use to derive the mortality 
rates along with some key parameters including treatment 
outcomes rely on data from high- income and middle- 
income settings, which may not be directly transferable to 
Malawi.3 21 26 Our results are sensitive to the assumptions 
inherent in these analyses and cannot yet be fully parame-
terised using data from African settings due to the limited 
numbers of cases there. Age- structured contact matrices 
are derived from studies in Zimbabwe, although we 
expect that there are unlikely to be significant differences 
between the two settings that would meaningfully affect 
the conclusions drawn. Household structure is not incor-
porated; therefore, we cannot adjust for increased risk of 
infection within households. This may be of particular 
importance in Malawi, where households are multigener-
ational and there may not be space to designate separate 
rooms for high- risk individuals. An important next step in 
this analysis would be the integration of the model with 
geographically disaggregated surveillance data on testing, 
deaths, movement and other data, which could capture 
local transmission and potentially open the way to more 
finely targeted interventions that may maximise epidemic 
control with lesser disruptions overall.
The estimates of relative risk of mortality with comor-
bidities are derived mainly from studies in high- income 
or upper- middle- income settings and may vary by age, 
although we do not capture this here. The management 
of comorbidities is likely to differ across settings, and so 
the corresponding risk of mortality with these conditions 
may vary also. The relative risks of death of the different 
comorbidities were combined in an additive model, given 
that the reported HRs used have been adjusted for the 
presence of other conditions.
The low numbers of cases reported in the first wave of 
the epidemic in Malawi could be consistent with a lower R
t
 
than is assumed here or an imperfect surveillance system 
with low numbers of tests being carried out. Approxi-
mately 1000 deaths have been reported throughout the 
whole outbreak, although this is likely an underestimate, 
with 82% of those occurring in 2021.47 We estimate here 
approximately 80 000 deaths may occur if stricter NPI 
are not introduced, falling to 48 000 if therapeutics effec-
tively moderate mortality rates. Introduction of a vaccine 
is likely to have a significant impact on the course of the 
epidemic and, if prioritised to those at highest risk, could 
substantially reduce the projected number of deaths.
This study has focused on the effects of NPI and health 
system capacity with respect to one disease, COVID-19. 
However, imposing lockdown could disrupt routine health 
services such as the provision of care for HIV, TB and 
malaria along with national immunisation programmes, 
compounding increases in mortality rates. Balancing the 
competing demands on health versus economic produc-
tivity, poverty and education is an extremely difficult 
decision, and we present these projections as a series of 
hypothetical scenarios which could be used to inform 
decision- making.
These outputs are not intended to be a forecast of what 
will happen in Malawi, and evidence should be reviewed 
in the light of continuously evolving surveillance data and 
combined with detailed analyses on the broader impacts 
of any potential interventions. Lessons could be learnt 
from the South African response, which implemented a 
rapid, phased strategy, successfully delaying the outbreak 
despite considerable challenges. In addition to physical 
distancing and restrictions on movement, South Africa 
capitalised on existing experienced teams of commu-
nity health workers to conduct active case finding, along 
with redirecting contact- tracing teams, previously estab-
lished for TB control, to conduct COVID-19 contact 
tracing and monitor quarantine compliance.44 Clearly, 
lockdown would have the biggest impact on the spread 
of SARS- CoV-2, but in settings where this is not feasible, 
a combination of interventions such as shielding, face 
covering, increasing hospital capacity and therapeutic 
agents could together have a significant impact on 
mortality.
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